[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021002665A - Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas. - Google Patents

Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.

Info

Publication number
MX2021002665A
MX2021002665A MX2021002665A MX2021002665A MX2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A MX 2021002665 A MX2021002665 A MX 2021002665A
Authority
MX
Mexico
Prior art keywords
annulene
oxyphenyl
pyrrolidin
dichlorophenyl
benzo
Prior art date
Application number
MX2021002665A
Other languages
English (en)
Inventor
Joël Malpart
Montes José Ruiz
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021002665A publication Critical patent/MX2021002665A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/1616—Coordination complexes, e.g. organometallic complexes, immobilised on an inorganic support, e.g. ship-in-a-bottle type catalysts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Pyrrole Compounds (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

En la presente memoria se proporcionan sales novedosas de 6-(2,4-diclorofenil)-5-[4-[(3S)-1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7H-benzo[7]anulen-2-carboxilato de metilo, concretamente la sal de oxalato (ver Fórmula) y la sal de dibenzoiltartrato. (ver Fórmulas).
MX2021002665A 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas. MX2021002665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306177 2018-09-07
PCT/EP2019/073823 WO2020049150A1 (en) 2018-09-07 2019-09-06 Salts of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate and preparation process thereof

Publications (1)

Publication Number Publication Date
MX2021002665A true MX2021002665A (es) 2021-07-16

Family

ID=63637829

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021002665A MX2021002665A (es) 2018-09-07 2019-09-06 Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.
MX2021002666A MX2021002666A (es) 2018-09-07 2019-09-06 Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021002666A MX2021002666A (es) 2018-09-07 2019-09-06 Proceso para la preparacion de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-( 3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]a nulen-2-carboxilato de metilo.

Country Status (19)

Country Link
US (2) US11713296B2 (es)
EP (2) EP3847157B1 (es)
JP (2) JP7413363B2 (es)
KR (2) KR20210057032A (es)
CN (2) CN112638870A (es)
AR (2) AR116299A1 (es)
AU (2) AU2019335542A1 (es)
BR (2) BR112021003061A2 (es)
CA (2) CA3111466A1 (es)
CY (2) CY1125418T1 (es)
DK (2) DK3847156T3 (es)
ES (2) ES2923412T3 (es)
HU (2) HUE059362T2 (es)
IL (2) IL281191B (es)
MX (2) MX2021002665A (es)
SG (2) SG11202102057SA (es)
TW (2) TW202026280A (es)
WO (2) WO2020049150A1 (es)
ZA (2) ZA202101006B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2021002665A (es) 2018-09-07 2021-07-16 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.
AU2020399168A1 (en) 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
US20230242507A1 (en) 2020-06-28 2023-08-03 Medshine Discovery Inc. Indazole-fused cyclic compound
EP4228758B1 (en) 2020-10-19 2024-07-24 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
US20240101512A1 (en) 2020-10-19 2024-03-28 Sanofi Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof
WO2023125700A1 (zh) 2021-12-28 2023-07-06 南京明德新药研发有限公司 四氢环庚吲唑化合物的盐型、晶型
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
WO2023198879A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198901A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted 4-amino-4-oxo-but-2-enyl derivatives, processes for their preparation and therapeutic uses thereof
WO2023198903A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n‑propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2023198904A1 (en) * 2022-04-15 2023-10-19 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
WO2023198905A1 (en) 2022-04-15 2023-10-19 Sanofi Novel substituted fluorinated vinyl-n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015579A1 (en) 1991-03-08 1992-09-17 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ES2236056T3 (es) 2001-01-24 2005-07-16 Chiesi Farmaceutici S.P.A. Derivados de 2h-1-benzopirano, procedimientos para su preparacion y composiciones farmaceuticas de los mismos.
EE200400061A (et) 2001-08-11 2004-04-15 Bristol-Myers Squibb Pharma Company Trifenüületüleeni derivaadid kui selektiivsed östrogeeniretseptori modulaatorid ja neid sisaldavad ravimkoostised
AU2003237084C1 (en) 2002-04-24 2009-03-26 Merck Sharp & Dohme Corp. Estrogen receptor modulators
AU2003292625B2 (en) 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
KR101229416B1 (ko) 2004-06-25 2013-02-05 얀센 파마슈티카 엔.브이. 사차염 ｃｃｒ２ 길항제
US7429681B2 (en) 2005-06-14 2008-09-30 Baylor University Combretastatin analogs with tubulin binding activity
US8127618B1 (en) 2007-05-18 2012-03-06 Pacesetter, Inc. Implantable micro-electromechanical system sensor
EP2048126A1 (de) 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
WO2009101634A2 (en) 2008-02-13 2009-08-20 Lupin Limited A novel process for the preparation of eszopiclone
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US20120130129A1 (en) 2010-11-16 2012-05-24 Baylor University Efficient Method for Preparing Functionalized Benzosuberenes
WO2012084711A1 (en) 2010-12-24 2012-06-28 Msd Oss B.V. N-substituted azetidine derivatives
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
KR20150039705A (ko) 2011-12-30 2015-04-13 켄타우루스 바이오파마 컴퍼니 리미티드 신규 아릴알켄 유도체 및 이의 선택성 에스트로겐 수용체 조절제에 있어서의 응용
AU2014307633A1 (en) 2013-08-14 2016-02-11 Novartis Ag Combination therapy for the treatment of cancer
WO2015028409A1 (de) 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CA2932106A1 (en) 2013-12-06 2015-06-11 F. Hoffmann-La Roche Ag Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
EP3233828B1 (en) 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Estrogen receptor modulators and uses thereof
CN112375077A (zh) 2014-12-18 2021-02-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
IL255261B2 (en) 2015-04-29 2024-03-01 Radius Pharmaceuticals Inc A combination of an m-TOR inhibitor and RAD1901 for use in a method to inhibit cancer growth or to produce tumor regression in patients with resistance to the drug and/or patients with cancer positive for an estrogen receptor alpha mutation
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
PT3416962T (pt) 2016-02-15 2021-07-23 Sanofi Sa Derivados de 6,7-di-hidro-5h-benzo[7]anuleno como moduladores do recetor de estrogénio
AU2017362460B2 (en) 2016-11-17 2021-07-22 Sanofi Novel substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
MX2021002665A (es) * 2018-09-07 2021-07-16 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.
TW202038951A (zh) 2018-11-16 2020-11-01 美商亞闊股份有限公司 用於治療癌症之醫藥組合
JP2022531898A (ja) 2019-05-09 2022-07-12 サノフイ 転移性または進行性乳房がん患者において使用するための６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸
EP4003525A1 (en) * 2019-07-22 2022-06-01 Sun Pharma Advanced Research Company Ltd Selective estrogen receptor degrader
WO2021091819A1 (en) * 2019-11-04 2021-05-14 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
AU2020399168A1 (en) * 2019-12-09 2022-07-28 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative

Also Published As

Publication number Publication date
SG11202102057SA (en) 2021-03-30
IL281196B2 (en) 2023-02-01
BR112021003440A2 (pt) 2021-05-18
EP3847157B1 (en) 2022-05-18
ES2923412T3 (es) 2022-09-27
JP2021536471A (ja) 2021-12-27
IL281191A (en) 2021-04-29
CA3111359A1 (en) 2020-03-12
AR116300A1 (es) 2021-04-21
TW202026280A (zh) 2020-07-16
JP2021536468A (ja) 2021-12-27
MX2021002666A (es) 2021-07-16
CN112638869A (zh) 2021-04-09
IL281196A (en) 2021-04-29
DK3847157T3 (da) 2022-08-08
EP3847156A1 (en) 2021-07-14
WO2020049153A1 (en) 2020-03-12
AU2019335542A1 (en) 2021-04-01
EP3847157A1 (en) 2021-07-14
EP3847156B1 (en) 2022-05-04
CA3111466A1 (en) 2020-03-12
CN112638870A (zh) 2021-04-09
US11713296B2 (en) 2023-08-01
JP7398436B2 (ja) 2023-12-14
DK3847156T3 (da) 2022-07-25
US20210188772A1 (en) 2021-06-24
AR116299A1 (es) 2021-04-21
CY1125418T1 (el) 2024-09-20
HUE059362T2 (hu) 2022-11-28
ZA202101006B (en) 2022-08-31
JP7413363B2 (ja) 2024-01-15
IL281191B (en) 2022-07-01
IL281196B (en) 2022-10-01
SG11202102059YA (en) 2021-03-30
TW202024032A (zh) 2020-07-01
BR112021003061A2 (pt) 2021-05-11
ZA202101079B (en) 2022-09-28
CY1125486T1 (el) 2024-09-20
KR20210057031A (ko) 2021-05-20
KR20210057032A (ko) 2021-05-20
US20210188771A1 (en) 2021-06-24
TWI803692B (zh) 2023-06-01
AU2019336532A1 (en) 2021-04-01
WO2020049150A1 (en) 2020-03-12
HUE059527T2 (hu) 2022-11-28
ES2924738T3 (es) 2022-10-10

Similar Documents

Publication Publication Date Title
MX2021002665A (es) Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirroli din-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anulen-2-carboxilato de metilo y proceso de preparación de las mismas.
MX2020009947A (es) Amidas heterocíclicas útiles como moduladores de proteínas.
EP4306111A3 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
MX2020008367A (es) Formas cristalinas novedosas.
EP4286372A3 (en) Pyrimidinones as factor xia inhibitors
PH12016502523A1 (en) Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
EP3950681A3 (en) Salts and solid forms of the compound (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
RS54030B1 (en) PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR CANCER TREATMENT
NO20063486L (no) Bicykloesterderivater
DK1599450T3 (da) Fremgangsmåde til fremstilling af 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxyethyl]-8-hydtroxy-(1H)-quinolin-2-on-salte, der kan anvendes som adrenoceptor-agonister
MX2019002697A (es) Composiciones para comprimidos.
MX2021012849A (es) Una 7-h-pirrolo[2,3-d]pirimidina inhibidora de jak.
WO2016100302A3 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
MX2021003453A (es) Derivados de ciclopropilmetilamida activos como pesticidas.
MX2020002010A (es) Procesos para la preparacion de 4,5-diamino-5-oxopentanoato de (s)-terc-butilo.
WO2019133629A8 (en) Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors
PE20070713A1 (es) 4-amino-5-cloro-n-{[1-(tetrahidro-2h-piran-4-ilmetil)-4-piperidinil]metil}-1-benzofuran-7-carboxamida en el tratamiento de alzheimer
EP3533790A3 (en) An improved process for preparation of chlorpromazine or its pharmaceutically acceptable salts
EP3848037A4 (en) SOLID PHARMACEUTICAL COMPOSITION WITH 1,3,5-TRIAZINE DERIVATE OR A SALT THEREOF
MA56071A (fr) Procédés de préparation de 3-bromo-1-(3-chloropyridine-2-yl)-1h-pyrazole-5-carboxylate d'éthyle
WO2020041683A3 (en) Acid addition salts of apomorphine, pharmaceutical compositions containing the same, and methods of using the same
DK1708987T3 (da) L-(-)-moprolol-L-(+)-tartrat